Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant347 active trials14 approved drugs74 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06171750 | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors(ANCHOR) | recruiting | Phase 1 | 97 | Ankyra Therapeutics, IncINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT06167096 | Effects of Lavender Aromatherapy on Patient Anxiety During Mohs Micrographic Surgery | completed | N/A | 89 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07441538 | Optimizing the Timing for Facial Surgical Dressing Removal | completed | N/A | 144 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02721459 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | active not recruiting | Phase 1 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07436390 | IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma(MAK) | completed | N/A | 132 | Institute of Oncology LjubljanaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03716193 | Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry | terminated | N/A | 3 | West Virginia UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06235281 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)(PLIGHT) | suspended | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07434323 | Lavender Aromatherapy for Preoperative Anxiety in Melanoma and Epithelioma Patients(LAPAM) | completed | N/A | 66 | San Gallicano Dermatological Institute IRCCSOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07428941 | Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.(LegitHealth PH) | completed | — | 9 | AI Labs Group S.LINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04354064 | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07422779 | Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia(MAK) | recruiting | N/A | 100 | Institute of Oncology LjubljanaOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06999980 | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)(Neo IRENIE) | recruiting | Phase 2 | 494 | Melanoma Institute AustraliaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07404605 | Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma | recruiting | N/A | 150 | Institute of Oncology LjubljanaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07415291 | CNN-Based AI Versus Physicians for Solitary Skin Lesion Diagnosis | active not recruiting | — | 17,625 | Istanbul Training and Research HospitalOTHER_GOV | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT07288073 | TIL Therapy in cSCC and MCC | recruiting | Phase 2 | 14 | Karam Khaddour, MD, MSOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07402616 | Ex Vivo Cutaneous SCC | recruiting | N/A | 30 | Rigshospitalet, DenmarkOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04848064 | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | recruiting | Phase 1 | 12 | John ReneauOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05872854 | Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light(RW-HPN-MF-01) | completed | Phase 2 | 10 | Ellen Kim, MDOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06485219 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | active not recruiting | Phase 2 | 50 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07394244 | Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 38 | Fudan UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | active not recruiting | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07222995 | Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs | recruiting | N/A | 2,900 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) | terminated | Phase 1 / Phase 2 | 46 | SanofiINDUSTRY | 7 | Feb 4, 2026 | clinicaltrials |
| NCT05296304 | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07204704 | EUREKA: Evaluating Ultraviolet Radiation Exposure in Kids for Adaptive Intervention(EUREKA) | completed | N/A | 78 | University of UtahOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07384078 | High Intensity Focused Ultrasound vs. Cryotherapy in the Treatment of Basal Cell Carcinomas and Bowen's Disease in Adults(HIFUvsCRYO) | not yet recruiting | N/A | 294 | Jussi SalonenOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07384299 | Impact of Skin Type on Wonud Healing and Scarring Following Facial Skin Surgery | completed | — | 173 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07381972 | Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma | recruiting | Phase 3 | 142 | University of Sao PauloOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07112690 | Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment | recruiting | N/A | 5 | Emory UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07376317 | Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)(OTIMAS) | active not recruiting | Phase 2 | 29 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03082534 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of California, San DiegoOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04670874 | Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29 | recruiting | — | 1,250 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05085496 | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | recruiting | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin | terminated | Phase 1 | 5 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07361666 | Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence(HFUS-CLEAR) | not yet recruiting | — | 400 | Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i AdministracjiOTHER_GOV | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | recruiting | — | 5,000 | MPN Research FoundationOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | withdrawn | Phase 2 | 0 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 0 | Jan 22, 2026 | clinicaltrials |
| NCT02636569 | Topical Chemoprevention of Skin Cancer Biomarkers | completed | Phase 2 | 24 | University of Alabama at BirminghamOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03889912 | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | completed | Phase 1 | 97 | Regeneron PharmaceuticalsINDUSTRY | 3 | Jan 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2026source: clinicaltrials